MarketPulse
R

$RXRX

5 articles found
3 positive
2 negative
0 neutral
The Motley FoolThe Motley Fool··Jeff Siegel

Three AI-Powered Healthcare Firms Positioned to Disrupt Medicine by 2030

Three tech-driven companies—Tempus AI, Recursion Pharmaceuticals, and Axsome Therapeutics—are positioned to reshape healthcare through AI, precision medicine, and faster drug discovery by 2030.
AXSMRXRXTEMCNS disordersprecision medicine
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Recursion Deepens Citeline Partnership to Supercharge AI Drug Discovery Platform

Recursion expands Citeline partnership to integrate real-world data into its AI drug discovery platform, achieving 30-60% trial enrollment improvements.
RXRXstrategic partnershipclinical development
The Motley FoolThe Motley Fool··James Brumley

AI Stock Correction Signals Generational Buying Opportunity as Market Enters 'Trough of Disillusionment'

AI stocks face a painful but historically productive "trough of disillusionment." Oracle and Alphabet positioned for 2026 recovery as investor reset creates potential generational buying opportunity.
MSFTGOOGGOOGLORCLORCLpD+3cloud computingAI infrastructure
BenzingaBenzinga··Erica Kollmann

ARK Innovation ETF Doubles S&P 500 Gains in 2025 Despite Portfolio Volatility

ARK Innovation ETF returned 35.5% in 2025, more than doubling S&P 500's 16.6%, driven by tech and fintech winners despite significant losses in other holdings.
AMDPLTRTTDSHOPHOOD+3outperformanceARK Innovation ETF
The Motley FoolThe Motley Fool··Rick Munarriz

Ark Invest Adds to Three Growth Stocks Trading Below 2025 Peaks

Ark Investment increased positions in Figma, CoreWeave, and Recursion Pharmaceuticals Friday, buying growth stocks trading below 2025 peaks based on valuation opportunities and emerging tech trends.
CRWVFIGRXRXAI infrastructurebiotech